JAZZ’s Xywav Gets Orphan Drug Exclusivity for Hypersomnia Posted byZacks Equity Research January 4, 2022 Leave a comment on JAZZ’s Xywav Gets Orphan Drug Exclusivity for Hypersomnia The FDA bestows an Orphan Drug Exclusivity to Jazz’s (JAZZ) Xywav for treating idiopathic hypersomnia in adults. This is the second Orphan Drug Exclusivity for the drug.